Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - In vitro studies of NXP002 as treatment for idiopathic pulmonary fibrosis have demonstrated that it is feasible to formulate the product into a simple solution for delivery via nebulisation.
In addition, in vivo studies of NXP002 showed that the drug could be efficiently delivered to the lung while limiting exposure compared to oral dosing, as well as regulate the production fibrosis-relevant mediators.
Currently, the final in vivo study of the durability of the pharmacodynamic effect of NXP002, and expects receiving the data for the study in early 2022.
"We're delighted with the positive readout of this data so far and it further cements our belief in NXP002 as a valuable asset. Tranilast is poorly soluble, meaning it is not well absorbed into the body and tissues, and it also has issues regarding systemic toxicity. NXP002 is a new form of tranilast that shows greater solubility than the original drug, allowing it to be delivered to the lungs that are the site of action for IPF," said Chief Executive Officer Anne Brindley.
Current stock price: 1.67 pence, up 15% on Thursday
Year-to-date change: down 38%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Nuformix (NFX)